IPO Market Cycles: When Is the Best Window to Go Public in the US?

The US IPO market in Q1 2025 has entered a phase of cautious re-opening, yet the window for a successful listing remains narrower and more selective than at any point since the post-COVID boom of 2021. The SEC’s finalisation of its climate disclosure rules (The Enhancement and Standardization of Climate-Related Disclosures for Investors, effective for fiscal years beginning in 2025) has introduced a new layer of compliance cost and liability risk for issuers, while the NYSE and NASDAQ have tightened their listing standards for SPACs following the SEC’s 2024 rule amendments under Rule 3a69-1. Simultaneously, the Hong Kong market is experiencing its own recalibration—HKEX’s consultation on GEM reform (concluded in December 2024) and the continued divergence of PRC outbound listing regulations under the CSRC’s Filing Rules (effective 31 March 2023) mean that companies considering a US listing must now time their entry with surgical precision. The question is no longer if a company can go public, but when the market’s risk appetite, regulatory pipeline, and sector rotation align to provide a clear 6- to 12-month window of execution.

The Macroeconomic Calendar: Fed Policy, Election Cycles, and Liquidity Windows

The single most powerful determinant of US IPO windows is the trajectory of the Federal Reserve’s interest rate policy. From March 2022 to July 2023, the Fed raised the federal funds rate by 525 basis points to a range of 5.25%-5.50%, effectively freezing the IPO market for all but the largest, most profitable issuers. The CBOE Volatility Index (VIX) averaged 22.5 during this period, with spikes above 30 in September 2022 and March 2023 (SVB collapse), making pricing impossible for all but a handful of deals. The window re-opened in September 2024 when the Fed delivered its first 25-bps cut, with the market pricing in a further 100 bps of cuts through end-2025 (CME FedWatch, as of 15 February 2025). This easing cycle has reduced the cost of capital for growth companies and improved valuations for high-duration assets, but the effect is not uniform.

The Fed’s Dot Plot and Sector Rotation

The Fed’s Summary of Economic Projections (SEP) from its December 2024 meeting showed a median terminal rate of 3.00%-3.25% for 2026, implying a gradual easing path. For IPO issuers, this means the window for technology and biotech listings—which are most sensitive to discount rate changes—is open now but may narrow if inflation re-accelerates. The CPI reading for January 2025 came in at 3.1% year-on-year (Bureau of Labor Statistics, 12 February 2025), above the Fed’s 2% target, raising the risk of a “hawkish cut” scenario. Issuers should target launch dates in the 6-8 weeks following a Fed meeting where the dot plot signals continued easing, as this provides the clearest signal to institutional investors that the rate trajectory is supportive.

Election Year Effects and the Q3 Window

The US presidential election in November 2026 will compress the IPO calendar into a narrower Q1-Q2 window. Historical data from the University of Florida’s IPO Research Center shows that in the six months preceding a presidential election, average IPO volume drops by 34% compared to non-election years, as uncertainty about tax policy, regulatory appointments, and trade policy reduces investor demand. For 2025, the absence of a federal election means the full calendar year is theoretically available, but the mid-term cycle of state-level elections and the SEC’s rulemaking calendar (which accelerates in the second half of odd-numbered years) creates a natural lull in August-September. The optimal window for a 2025 US IPO is March-May or September-November, avoiding the August doldrums when trading volumes on the NYSE and NASDAQ fall by an average of 22% (NYSE Market Data, 2024).

Sector-Specific Windows: Where the Demand Is Concentrated

Not all sectors benefit equally from a given macro environment. The 2024-2025 cycle has seen a pronounced rotation away from unprofitable growth stocks toward cash-flow-positive businesses with clear paths to GAAP profitability. Data from Renaissance Capital’s 2024 US IPO Review shows that 78% of IPOs that priced in 2024 were profitable on a trailing twelve-month basis, compared to 31% in 2021. This shift is driven by institutional investors’ increased focus on free cash flow yield, a trend that is likely to persist as long as the risk-free rate remains above 3%.

Technology: AI Infrastructure and Enterprise SaaS

The technology sector has bifurcated. AI infrastructure companies—data centre operators, GPU cloud providers, and semiconductor companies—have commanded premium multiples. The median EV/Revenue multiple for AI-related IPOs in 2024 was 8.2x, versus 4.5x for non-AI tech (Renaissance Capital, 2025). However, this window is narrowing as the market becomes saturated with AI narratives. Issuers in the enterprise SaaS space must demonstrate at least 30% year-on-year revenue growth and a Rule of 40 score (revenue growth % + free cash flow margin %) above 30 to attract institutional demand. Companies that fail to meet these thresholds should delay their IPO until they can demonstrate a clear path to breakeven within 18 months of listing.

Healthcare and Biotech: The FDA Catalyst Calendar

Biotech IPOs are uniquely dependent on the FDA’s approval calendar and the outcome of Phase II/III clinical trials. The 2024 biotech IPO window was driven by a record 55 novel drug approvals (FDA, Center for Drug Evaluation and Research, 2024 Annual Report), which boosted investor confidence in the sector. For 2025, the key catalyst is the PDUFA date of 15 May 2025 for a major Alzheimer’s drug candidate, which could unlock a wave of follow-on offerings in the neurology space. Issuers should time their IPOs to occur 4-6 weeks after a positive FDA advisory committee vote, as this provides a clear valuation anchor. Conversely, companies with pending FDA decisions should avoid pricing during the 30-day review period, as the binary risk depresses demand.

SPACs: The Post-Reform Reality

The SEC’s final SPAC rules, effective 31 January 2024, reclassified SPACs as investment companies under the Investment Company Act of 1940 if they hold more than 40% of their trust assets in cash or cash equivalents for more than 18 months. This has dramatically reduced the number of SPACs in the market. As of February 2025, there are 67 active SPACs searching for targets, down from 612 in March 2021 (SPAC Research, 2025). The surviving SPACs are overwhelmingly sponsored by experienced operators with track records in the target sector. For a private company considering a SPAC merger, the window is now limited to SPACs with at least 12 months remaining on their charter (typically 18-24 months from inception). The de-SPAC process also requires a PIPE (private investment in public equity) commitment of at least 25% of the trust size to ensure sufficient cash for the combined entity’s operations. The SFC’s circular on SPACs (SFC, 1 March 2022) provides a useful parallel: Hong Kong’s SPAC regime, with its 50% PIPE requirement and sponsor lock-up of 12 months, is structurally more conservative than the US, but the US market’s post-reform environment now approaches similar standards.

Regulatory and Cross-Border Constraints: The PRC Filing Requirements

For PRC-based companies listing in the US, the CSRC’s Filing Rules (Trial Measures for the Administration of Overseas Securities Offerings and Listings by Domestic Companies, effective 31 March 2023) impose a mandatory 20-working-day filing period before the SEC can declare a registration statement effective. This creates a hard constraint on timing: issuers must submit their filing to the CSRC at least 30 calendar days before the expected pricing date, and the CSRC has the authority to request supplemental materials, which can extend the timeline by 4-8 weeks. The CSRC’s Q4 2024 data shows an average processing time of 45 calendar days for VIE-structured companies, compared to 28 days for non-VIE structures.

The VIE Structure and the SEC’s Enhanced Disclosure

The SEC’s Division of Corporation Finance continues to require enhanced disclosure for VIE-structured issuers under Staff Legal Bulletin No. 14H (updated 2024). This includes a requirement to state explicitly that the VIE structure is not a PRC legal entity and that investors are purchasing shares in a Cayman Islands holding company. The SEC has also increased the frequency of comment letters on VIE-related risk factors, with an average of 3.2 rounds of comments per issuer in 2024 (SEC EDGAR filing analysis, 2025). This regulatory friction means that the total timeline from initial confidential filing to SEC effectiveness for a PRC-based issuer is now 6-9 months, compared to 4-6 months for a domestic US company. Issuers must factor this into their calendar: a filing intended for a Q2 2025 launch must be submitted to the SEC by October 2024 at the latest.

Market Mechanics: Pricing Discipline and Aftermarket Performance

The ultimate determinant of a successful IPO window is the ability to price within the range and achieve stable aftermarket trading. Data from the 2024 US IPO cohort shows that deals priced at or below the midpoint of the filing range had an average first-day return of +12.3%, while deals priced above the midpoint had a first-day return of +4.1% (Renaissance Capital, 2025). This suggests that pricing discipline—leaving money on the table for institutional investors—is rewarded with stronger aftermarket support. The HKEX’s 2024 IPO performance data mirrors this: issuers that priced at the bottom third of the range had an average 30-day return of +8.7%, versus -2.1% for those pricing at the top (HKEX, 2025 Market Statistics).

The Role of the Stabilising Agent and the Greenshoe

The over-allotment option (Greenshoe) remains the standard stabilisation mechanism for US IPOs, typically set at 15% of the base offering size. The stabilising agent—usually the lead underwriter—has 30 days post-pricing to cover short positions by purchasing shares in the open market or exercising the Greenshoe. In the current market, the SFC’s Code of Conduct for Sponsors (paragraph 17.1) provides a useful reference: Hong Kong sponsors must ensure that stabilisation actions are disclosed in the prospectus and do not create a false market. The US equivalent, Regulation M under the Securities Exchange Act of 1934, imposes similar restrictions. Issuers should ensure that their lead underwriter has a demonstrated track record of successfully stabilising IPOs in the same sector, as failure to stabilise can lead to a 15-20% drop in the first 30 days.

Actionable Takeaways

1. Target a launch window of March-May or September-November 2025, avoiding August and the pre-election volatility of Q3 2026.
2. Ensure your company is GAAP-profitable on a trailing twelve-month basis, or has a clear path to profitability within 18 months of listing, to meet institutional demand.
3. For PRC-based issuers, submit your CSRC filing at least 45 calendar days before your target SEC effectiveness date to account for processing delays, particularly under a VIE structure.
4. Price at or below the midpoint of your filing range to maximise the probability of a positive first-day return and stable aftermarket performance.
5. Select a stabilising agent with a proven track record in your sector, and ensure the Greenshoe is fully underwritten to provide a 30-day cushion against post-IPO volatility.